Cadent Therapeutics

Cadent Therapeutics

Cadent Therapeutics

Cognitive and Movement Disorders Affect Millions We are rapidly advancing a pipelineof novel allosteric modulators of ion channels taking a wellestablished pharmaceutical approach and stepping out into new territory.SK channels and NMDA receptors are ion
Founded
2010
Raised
$55M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$15,000,000
Venture capital (Series B) - 2020
Access Industries Atlas Venture QiMing Venture Partners +3
$40,000,000
Venture capital (Series B) - 2018
Access Industries Atlas Venture QiMing Venture Partners +3
Team Size
1–10
Employees
$15,000,000 Venture capital (Series B)
Pulse 2.0

Biopharmaceutical Company Cadent Therapeutics Raises $15 Million

$40,000,000 Venture capital (Series B)
FinSMEs , PE HUB

Cadent Therapeutics Secures $40M Series B Financing